Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney

Akira Yokomizo, Michiko Takakura, Yae Kanai, Tomohiro Sakuma, Junichi Matsubara, Kazufumi Honda, Seiji Naito, Tesshi Yamada, Masaya Ono

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Early detection would be one of the most effective means to improve the outcome of renal cell carcinoma (RCC). We searched for a new plasma marker for RCC using a label-free quantitative shotgun proteomics method. Methods: Plasma proteins were digested by trypsin, and the resulting peptides were analyzed by 2-Dimensional Image Converted Analysis of Liquid chromatography mass spectrometry (2DICAL). An identified biomarker candidate was subjected to validation using the Amplified Luminescent Proximity Homogeneous Assay (AlphaLISA). Results: Among a total of 23,407 independent MS peaks, we found that the mean intensity of 59~peaks significantly differed between 20 clear cell RCC patients and 20~healthy controls. MS/MS spectra from 16 of the 59~peaks matched the amino acid sequences of the fibronectin 1 (FN1) gene product. {The increased plasma level of FN1 in RCC patients was validated in a cohort of in 77 patients and 130 healthy controls (p<0.0001).} Conclusions: The FN1 is considered to be a promising biomarker candidate for clear cell RCC. Furthermore, AlphaLISA is an alternate to the conventional enzyme-linked immunosorbent assay and should prove useful for the rapid validation of biomarker candidates.

Original languageEnglish
Pages (from-to)175-183
Number of pages9
JournalCancer Biomarkers
Volume10
Issue number3-4
DOIs
Publication statusPublished - Dec 1 2011

Fingerprint

Firearms
Fibronectins
Renal Cell Carcinoma
Proteomics
Biomarkers
Carcinoma
Kidney
Liquid Chromatography
Trypsin
Blood Proteins
Amino Acid Sequence
Mass Spectrometry
Enzyme-Linked Immunosorbent Assay
Peptides
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney. / Yokomizo, Akira; Takakura, Michiko; Kanai, Yae; Sakuma, Tomohiro; Matsubara, Junichi; Honda, Kazufumi; Naito, Seiji; Yamada, Tesshi; Ono, Masaya.

In: Cancer Biomarkers, Vol. 10, No. 3-4, 01.12.2011, p. 175-183.

Research output: Contribution to journalArticle

Yokomizo, A, Takakura, M, Kanai, Y, Sakuma, T, Matsubara, J, Honda, K, Naito, S, Yamada, T & Ono, M 2011, 'Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney', Cancer Biomarkers, vol. 10, no. 3-4, pp. 175-183. https://doi.org/10.3233/CBM-2012-0243
Yokomizo, Akira ; Takakura, Michiko ; Kanai, Yae ; Sakuma, Tomohiro ; Matsubara, Junichi ; Honda, Kazufumi ; Naito, Seiji ; Yamada, Tesshi ; Ono, Masaya. / Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney. In: Cancer Biomarkers. 2011 ; Vol. 10, No. 3-4. pp. 175-183.
@article{76d42db73e454436a6f9d1147a722a17,
title = "Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney",
abstract = "Background: Early detection would be one of the most effective means to improve the outcome of renal cell carcinoma (RCC). We searched for a new plasma marker for RCC using a label-free quantitative shotgun proteomics method. Methods: Plasma proteins were digested by trypsin, and the resulting peptides were analyzed by 2-Dimensional Image Converted Analysis of Liquid chromatography mass spectrometry (2DICAL). An identified biomarker candidate was subjected to validation using the Amplified Luminescent Proximity Homogeneous Assay (AlphaLISA). Results: Among a total of 23,407 independent MS peaks, we found that the mean intensity of 59~peaks significantly differed between 20 clear cell RCC patients and 20~healthy controls. MS/MS spectra from 16 of the 59~peaks matched the amino acid sequences of the fibronectin 1 (FN1) gene product. {The increased plasma level of FN1 in RCC patients was validated in a cohort of in 77 patients and 130 healthy controls (p<0.0001).} Conclusions: The FN1 is considered to be a promising biomarker candidate for clear cell RCC. Furthermore, AlphaLISA is an alternate to the conventional enzyme-linked immunosorbent assay and should prove useful for the rapid validation of biomarker candidates.",
author = "Akira Yokomizo and Michiko Takakura and Yae Kanai and Tomohiro Sakuma and Junichi Matsubara and Kazufumi Honda and Seiji Naito and Tesshi Yamada and Masaya Ono",
year = "2011",
month = "12",
day = "1",
doi = "10.3233/CBM-2012-0243",
language = "English",
volume = "10",
pages = "175--183",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "3-4",

}

TY - JOUR

T1 - Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney

AU - Yokomizo, Akira

AU - Takakura, Michiko

AU - Kanai, Yae

AU - Sakuma, Tomohiro

AU - Matsubara, Junichi

AU - Honda, Kazufumi

AU - Naito, Seiji

AU - Yamada, Tesshi

AU - Ono, Masaya

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background: Early detection would be one of the most effective means to improve the outcome of renal cell carcinoma (RCC). We searched for a new plasma marker for RCC using a label-free quantitative shotgun proteomics method. Methods: Plasma proteins were digested by trypsin, and the resulting peptides were analyzed by 2-Dimensional Image Converted Analysis of Liquid chromatography mass spectrometry (2DICAL). An identified biomarker candidate was subjected to validation using the Amplified Luminescent Proximity Homogeneous Assay (AlphaLISA). Results: Among a total of 23,407 independent MS peaks, we found that the mean intensity of 59~peaks significantly differed between 20 clear cell RCC patients and 20~healthy controls. MS/MS spectra from 16 of the 59~peaks matched the amino acid sequences of the fibronectin 1 (FN1) gene product. {The increased plasma level of FN1 in RCC patients was validated in a cohort of in 77 patients and 130 healthy controls (p<0.0001).} Conclusions: The FN1 is considered to be a promising biomarker candidate for clear cell RCC. Furthermore, AlphaLISA is an alternate to the conventional enzyme-linked immunosorbent assay and should prove useful for the rapid validation of biomarker candidates.

AB - Background: Early detection would be one of the most effective means to improve the outcome of renal cell carcinoma (RCC). We searched for a new plasma marker for RCC using a label-free quantitative shotgun proteomics method. Methods: Plasma proteins were digested by trypsin, and the resulting peptides were analyzed by 2-Dimensional Image Converted Analysis of Liquid chromatography mass spectrometry (2DICAL). An identified biomarker candidate was subjected to validation using the Amplified Luminescent Proximity Homogeneous Assay (AlphaLISA). Results: Among a total of 23,407 independent MS peaks, we found that the mean intensity of 59~peaks significantly differed between 20 clear cell RCC patients and 20~healthy controls. MS/MS spectra from 16 of the 59~peaks matched the amino acid sequences of the fibronectin 1 (FN1) gene product. {The increased plasma level of FN1 in RCC patients was validated in a cohort of in 77 patients and 130 healthy controls (p<0.0001).} Conclusions: The FN1 is considered to be a promising biomarker candidate for clear cell RCC. Furthermore, AlphaLISA is an alternate to the conventional enzyme-linked immunosorbent assay and should prove useful for the rapid validation of biomarker candidates.

UR - http://www.scopus.com/inward/record.url?scp=84862868775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862868775&partnerID=8YFLogxK

U2 - 10.3233/CBM-2012-0243

DO - 10.3233/CBM-2012-0243

M3 - Article

C2 - 22674303

AN - SCOPUS:84862868775

VL - 10

SP - 175

EP - 183

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 3-4

ER -